These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18513392)

  • 1. Simpson's paradox visualized: the example of the rosiglitazone meta-analysis.
    Rücker G; Schumacher M
    BMC Med Res Methodol; 2008 May; 8():34. PubMed ID: 18513392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis, Simpson's paradox, and the number needed to treat.
    Altman DG; Deeks JJ
    BMC Med Res Methodol; 2002; 2():3. PubMed ID: 11860606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simpson's paradox and calculation of number needed to treat from meta-analysis.
    Cates CJ
    BMC Med Res Methodol; 2002; 2():1. PubMed ID: 11860604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Misleading Epidemiological and Statistical Evidence in the Presence of Simpson's Paradox: An Illustrative Study Using Simulated Scenarios of Observational Study Designs.
    Rojanaworarit C
    J Med Life; 2020; 13(1):37-44. PubMed ID: 32341699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
    Diamond GA; Bax L; Kaul S
    Ann Intern Med; 2007 Oct; 147(8):578-81. PubMed ID: 17679700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
    Nissen SE; Wolski K
    Arch Intern Med; 2010 Jul; 170(14):1191-1201. PubMed ID: 20656674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical issues regarding rosiglitazone meta-analysis.
    Claggett B; Wei LJ
    Arch Intern Med; 2011 Jan; 171(2):179-80; author reply 180. PubMed ID: 21263111
    [No Abstract]   [Full Text] [Related]  

  • 9. Simpson's paradox and experimental research.
    Ameringer S; Serlin RC; Ward S
    Nurs Res; 2009; 58(2):123-7. PubMed ID: 19289933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The nature of truth: Simpson's Paradox and the limits of statistical data.
    Heydtmann M
    QJM; 2002 Apr; 95(4):247-9. PubMed ID: 11937652
    [No Abstract]   [Full Text] [Related]  

  • 11. Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.
    McGuire DK
    Diab Vasc Dis Res; 2007 Jun; 4(2):77-9. PubMed ID: 17654438
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosiglitazone and cardiovascular risk.
    Diamond GA; Kaul S
    N Engl J Med; 2007 Aug; 357(9):938-9; author reply 939-40. PubMed ID: 17806135
    [No Abstract]   [Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
    Mannucci E; Monami M; Di Bari M; Lamanna C; Gori F; Gensini GF; Marchionni N
    Int J Cardiol; 2010 Aug; 143(2):135-40. PubMed ID: 19328563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone: a thunderstorm from scarce and fragile data.
    Mulrow CD; Cornell J; Localio AR
    Ann Intern Med; 2007 Oct; 147(8):585-7. PubMed ID: 17938398
    [No Abstract]   [Full Text] [Related]  

  • 16. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
    Stone JC; Furuya-Kanamori L; Barendregt JJ; Doi SA
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):223-7. PubMed ID: 25515780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inaccuracy in meta-analysis on rosiglitazone and myocardial infarction.
    Monami M; Bigiarini M; Rotella CM; Mannucci E
    Nutr Metab Cardiovasc Dis; 2011 Feb; 21(2):e7-8. PubMed ID: 21186111
    [No Abstract]   [Full Text] [Related]  

  • 18. Rosiglitazone and cardiovascular risk.
    Kaul S; Diamond GA
    Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
    Nissen SE; Wolski K
    N Engl J Med; 2007 Jun; 356(24):2457-71. PubMed ID: 17517853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone and cardiovascular risk.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.